Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma. (Q38906557)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25711293%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

title

Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25711293%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25711293%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Holger Lode

series ordinal

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25711293%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

1

Diana Seidel

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25711293%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

2

Anastasia Shibina

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25711293%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

6

Nicole Huebener

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25711293%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

author name string

Nikolai Siebert

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25711293%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

Winfried S Wels

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25711293%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

publication date

25 February 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25711293%20AND%20SRC:MED&resulttype=core&format=json

Cancer Immunology, Immunotherapy

1 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25711293%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

volume

64

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25711293%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25711293%20AND%20SRC:MED&resulttype=core&format=json

1 March 2020

page(s)

621-634

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25711293%20AND%20SRC:MED&resulttype=core&format=json

Genetic parameters of neuroblastomas

1 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Pediatric neuroblastomas: genetic and epigenetic 'danse macabre'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Natural killer cells in antiviral defense: function and regulation by innate cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Biology of natural killer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Mechanisms of granule-dependent killing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Regulation of death receptor-mediated apoptosis pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

In vivo natural killer cell activities revealed by natural killer cell-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Treatment of patients with advanced cancer with the natural killer cell line NK-92.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Elevated TGF-beta1 secretion and down-modulation of NKG2D underlies impaired NK cytotoxicity in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Chimeric antigen receptors for the retargeting of cytotoxic effector cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

NK cells engineered to express a GD2 -specific antigen receptor display built-in ADCC-like activity against tumour cells of neuroectodermal origin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Histone deacetylase 1 gene expression and sensitization of multidrug-resistant neuroblastoma cell lines to cytotoxic agents by depsipeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Vaccination with anti-idiotype antibody ganglidiomab mediates a GD(2)-specific anti-neuroblastoma immune response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Mechanisms of immune evasion of human neuroblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Natural killer lymphocytes: biology, development, and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Novel approaches using natural killer cells in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Natural killer cell-based immunotherapy in cancer: current insights and future prospects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Natural killer cell allorecognition of missing self in allogeneic hematopoietic transplantation: a tool for immunotherapy of leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Ex-vivo expanded human NK cells express activating receptors that mediate cytotoxicity of allogeneic and autologous cancer cell lines by direct recognition and antibody directed cellular cytotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

IL-2-activated haploidentical NK cells restore NKG2D-mediated NK-cell cytotoxicity in neuroblastoma patients by scavenging of plasma MICA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

2B4 (CD244) signaling by recombinant antigen-specific chimeric receptors costimulates natural killer cell activation to leukemia and neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Growth and activation of natural killer cells ex vivo from children with neuroblastoma for adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Expansion of highly cytotoxic human natural killer cells for cancer cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Biology and clinical effects of natural killer cells in allogeneic transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Natural killer cell biology: an update and future directions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Cellular Immunotherapy of Malignancies Using the Clonal Natural Killer Cell Line NK-92

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00262-015-1669-5

10.1007/S00262-015-1669-5

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25711293%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

1 March 2020

1017423879

0 references

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25711293%20AND%20SRC:MED&resulttype=core&format=json